Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2021 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus

Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...
November 22, 2021 07:00 ET | Source: Sab Biotherapeutics, Inc.

SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update

Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis Awarded additional $60.5 million from DoD in expanded...
October 25, 2021 07:40 ET | Source: Sab Biotherapeutics, Inc.

SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D.,...